Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Unraveling the mechanism of JPI-547 in human pancreatic cancer cells through transcriptome analysis.

ABSTRACT: This study aimed to elucidate the mechanism underlying the action of the dual PARP/Tankyrase inhibitor JPI-547 through RNA-sequencing. Focusing on human pancreatic cancer cell lines with either homologous recombination repair deficiency or Wnt-addiction, the investigation sought to uncover critical insights into the compound's mode of action.

ORGANISM(S): Homo sapiens

PROVIDER: GSE254997 | GEO | 2025/02/28

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Human Tankyrases TAP-LC-MSMS - Proteomic Analysis of the Human Tankyrase Protein Interaction Network Reveals Its Role in Pexophagy

Project description:Tankyrase 1 (TNKS1) and tankyrase 2 (TNKS2) belong to the poly(ADP-ribose) polymerase (PARP) family of proteins, which use NAD+ to modify substrate proteins with ADP-ribose modifications. Tankyrases are implicated involving in multiple cellular functions, including the telomere length control, Wnt/b-catenin pathway regulation, glucose uptake and cell cycle regulation. Emerging evidences reveal the pathological relevance of tankyrase in diseases and propose these two key enzymes as potential drug targets. However, the cellular functions and regulatory machineries of tankyrases are still largely unknown. Through this proteomic analysis, we not only defined the protein-protein interaction map for the tankyrases which revealed 100~150 high confident interacting proteins for tankyrases in various cellular functions, but also uncovered the novel regulating function of tankyrase in peroxisome homeostasis.

2017-07-24 | PXD004647 | Pride

Transcriptomics profiling of ccc_R08 for mechanism-of-action investigation with forward pharmacology

Project description:To investigate the mode of action of ccc_R08, a first-in-class orally available HBV cccDNA inhibitor, we designed and implemented two orthogonal and complementary approaches: a forward pharmacology approach and a reverse pharmacology approach. Bioinformatics analysis integrating biological knowledge with the observations from both approaches offered us preliminary insights into the mode of action of ccc_R08.

2022-12-30 | GSE214515 | GEO

Oncogenic IDH mutations increase heterochromatin-related replication stress without impacting tumor mutation burden

Project description:Oncogenic mutations in the metabolic enzyme isocitrate dehydrogenase 1 and 2 (IDH1/2) have been found in a number of liquid and solid tumors. Their pathogenic mechanism of action involves production of 2-hydroxyglutarate (2HG), an oncometabolite that acts in part by inhibiting members of a family of dioxygenases that modulate chromatin dynamics. Recent work has suggested that mutant IDH (mIDH) and 2HG also impact sensitivity to inhibitors of poly-ADP ribose polymerases (PARP) but the molecular basis for this sensitivity is unclear. Unlike PARP inhibitor-sensitive BRCA1/2 tumors which exhibit impaired homologous recombination, IDH-mutant tumors have a silent mutational profile and lack mutational signatures associated with impaired homologous recombination. Instead, 2HG-producing IDH mutations lead to heterochromatin-dependent slowing of DNA replication and increased replication stress, resulting in DNA double strand breaks. This replicative stress manifests as replication fork slowing but the breaks are repaired without a significant increase in the cellular mutation burden. Faithful resolution of replicative stress in IDH-mutant cells is dependent on poly-ADP ribosylation. Treatment with PARP inhibitors restores replication fork speed but results in incomplete repair of DNA breaks. These findings provide evidence of a requirement for PARP in the replication of heterochromatin and further validate PARP as a potential therapeutic target in IDH-mutant tumors.

2023-08-28 | GSE211592 | GEO

Project description:Mode of action of resveratrol

| PRJNA986468 | ENA

Mechanism of Oncogene Addiction

Project description:Mechanism of Oncogene Addiction

| PRJNA302297 | ENA

Praziquantel mode of action and resistance

Project description:Praziquantel mode of action and resistance

| PRJEB1281 | ENA

Project description:Mode of toxic action assignment of chemicals

| PRJNA305350 | ENA

Integrated transcriptomic and proteomic analysis revealed the inhibition mechanism of a natural luvangetin from Zanthoxylum avicennae against Fusarium verticillioides

Project description:(i) To determine the inhibitory effect of Luvangetin against Fusarium verticillioides and fumonisins production in vitro and in vivo, and (ii) to investigate the mode of action of Luvangetin against Fusarium verticillioides by transcriptomics and proteomics analysis.

2023-11-15 | GSE247362 | GEO

Target genes of thyroid hormone (TH) in white adipose tissue (WAT) and striatum and their role during metabolic stressors

Project description:We gathered in a single database available RNAseq and ChIPseq data to better characterize the target genes of the thyroid hormone receptors in several cell types. This database can serve as a resource to analyze the mode of action of the hormone. Also, it is an easy-handling convenient tool to obtain information on specific genes in regards to T3 regulation, or extract larger list of genes of interest based on the users’ criteria. Overall, this atlas is a unique compilation of recent sequencing data focusing on thyroid hormones, their receptors, mode of action, targets and roles which may profit researchers within the field. A preliminary analysis indicates extensive variations in the repertoire of target genes which transcription is upregulated by chromatin-bound nuclear receptor. Although it has a major influence, chromatin accessibility is not the only parameter that determines the cellular selectivity of hormonal response.

2022-08-12 | GSE210976 | GEO

Atlas of target genes of thyroid hormone (TH) in mice

2022-08-12 | GSE210975 | GEO